![Reverse-Phase Chromatographic Determination and Intrinsic Stability Behavior of 5-[(4-Chlorophenoxy)Methyl]-1,3,4-Oxadiazole-2-Thiol Cover](https://sciendo-parsed.s3.eu-central-1.amazonaws.com/6470768571e4585e08a9db5a/cover-image.jpg)
References
- 1. S. Z. Siddiqui, M. A. Abbasi, A. Rehman, M. Irshad, M. Ashraf, I. Ahmad, M. A. Lodhi, B. Mirza, H. Ismail, M. N. Akhtar and B. Shahzad, Synthesis, pharmacological evaluation, molecular docking and cytotoxicity studies on some N-substituted 5-[(4-chlorophenoxy)methyl]1,3,4-oxadiazole- 2yl-2-sulfanyl acetamides, Indo. Am. J. Pharm. Res. 4 (2014) 3603-3617.
- 2. C. S. de Oliveira, B. F. Lira, J. M. Barbosa-Filho, J. G. F. Lorenzo and P. F. de Athayde-Filho, Synthetic approaches and pharmacological activity of 1,3,4-oxadiazoles: A review of the literature from 2000-2012, Molecules 17 (2012) 10192-10231; https//doi.org/10.3390/molecules17091019210.3390/molecules170910192
- 3. A. Savarino, A historical sketch of the discovery and development of HIV-1 integrase inhibitors, Expert Opin. Investig. Drugs 15 (2004) 1507-1522; https//doi.org/10.1517/13543784.15.12.150710.1517/13543784.15.12.1507
- 4. E. D. Chrysina, M. N. Kosmopoulou, C. Tiraidis, R. Kardakaris, N. Bischler, D. D. Leonidas, Z. Hadady, L. Somsak, T. Docsa, P. Gergely and N. G. Oikonomakos, Kinetic and crystallographic studies on 2-(β-D-glucopyranosyl)-5-methyl-1,3,4-oxadiazole, -benzothiazole, and -benzimidazole, inhibitors of muscle glycogen phosphorylase b. Evidence for a new binding site, Protein Sci. 14 (2005) 873-888; https//doi.org/10.1110/ps.04121610510.1110/ps.041216105
- 5. N. D. James and J. W. Growcott, Zibotentan, Drugs Fut. 34 (2009) 624-633; https//doi.org/10.1358/ dof.2009.034.08.140020210.1358/dof.2009.34.8.1400202
- 6. R. R. Somani and P. Y. Shirodkar, Oxadiazole: A biologically important heterocycle, Pharma Chem. 1 (2009) 130-140.
- 7. N. Shehzadi, K. Hussain, M. Islam, N. I. Bukhari, M. T. Khan, M. Salman, S. Z. Siddiqui, A. Rehman and M. A. Abbasi, In silico drug-qualifying parameters of 5-[(4-chlorophenoxy)methyl]-1,3,4- oxadiazole-2-thiol, Lat. Am. J. Pharm. 35 (2016) 1991-1997.
- 8. Center for Drug Evaluation and Research (CDER), Reviewer Guidance: Validation of Chromatographic Methods, Rockville, MD, 1994; http://www.fda.gov/downloads/Drugs/.../Guidances/UCM134409.pdf; last access date March 10, 2018.
- 9. Food and Drug Administration (FDA), Guidance for Industry, Analytical Procedures and Methods Validation: Chemistry, Manufacturing and Controls Documentation, in Draft Guidance, Rockville, MD, 2000.
- 10. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonized Tripartite Guideline, Validation of Analytical Procedures: Text and Methodology Q2(R1), Current Step 4 version, Nov. 1996, Geneva, Nov. 2005; http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1_Guideline.pdf; last access date March 10, 2018.
- 11. S. Singh and M. Bakshi, Stress test to determine inherent stability of drugs, Pharm. Technol. 4 (2000) 1-14.
- 12. M. Bakshi, B. Singh, A. Singh and S. Singh, The ICH guidance in practice: stress degradation studies on ornidazole and development of a validated stability-indicating assay, J. Pharm. Biomed. Anal. 26 (2001) 891-897; https://doi.org/10.1016/S0731-7085(01)00475-710.1016/S0731-7085(01)00475-7
- 13. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonized Tripartite Guideline, Stability Testing of New Drug Substances and Products ICH Q1A (R2), Current Step 4 version, Sep 1992, Geneva, Feb 2003; https:// www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q1A_R2/Step4/Q1A_R2__Guideline.pdf; last access date March 9, 2018.
- 14. K. K. Hotha, S. P. K. Reddy, V. K. Raju and L. K. Ravindranath, Forced degradation studies: Practical approach-overview of regulatory guidance and literature for the drug products and drug substances, Int. Res. J. Pharm. 4 (2013) 78-85.10.7897/2230-8407.04517
- 15. J. J. Pignatello, Dark and photoassisted iron(3+)-catalyzed degradation of chlorophenoxy herbicides by hydrogen peroxide, Environ. Sci. Technol. 26 (1992) 944-951; https//doi.org/10.1021/ es00029a01210.1021/es00029a012
- 16. Z. D. Okram, B. Kanakapura, R. P. Jagannathamurthy and V. K. Basavaiah, Development of a simple UV-spectrophotometric method for the determination of lansoprazole and study of its degradation profile, Quím. Nova 35 (2012) 386-391; https://doi.org/10.1590/S0100-4042201200020002710.1590/S0100-40422012000200027
- 17. K. L. Maier, E. Matejkva, H. Hinze, L. Leuschel, H. Weber and I. Beck-Speier, Different selectivities of oxidants during oxidation of methionine residues in the α-1-proteinase inhibitor, FEBS Lett. 250 (1989) 221-226.10.1016/0014-5793(89)80725-2
- 18. C. M. Maciolek, B. Ma, K. Menzel, S. Laliberte, K. Bateman, P. Krolikowski and C. R. Gibson, Novel cytochrome P450-mediated ring opening of the 1,3,4-oxadiazole in setileuton, a 5-lipoxygenase inhibitor, Drug Metab. Dispos. 39 (2011) 763-770; https://doi.org/10.1124/dmd.110.03736610.1124/dmd.110.03736621325431
- 19. A. Corma, T. Ródenas and M. J. Sabater, Aerobic oxidation of thiols to disulfides by heterogeneous gold catalysts, Chem. Sci. 3 (2012) 398-404; http://doi.org/10.1039/C1SC00466B10.1039/C1SC00466B
- 20. R. Kumar and S. L. Khokara, Chemistry and common synthetic route of 1,3,4-oxadiazole: an important heterocyclic moiety in medicinal chemistry, Int. J. Inst. Pharm. Life Sci. 2 (2005) 224-230.